What is the TEGSEDI-PRG Pregnancy Observational Study

The TEGSEDI-PRG pregnancy observational study was developed by Akcea Therapeutics, Inc. to follow patients who have been exposed to at least one dose of TEGSEDI® (inotersen) during their pregnancy (or patients who became pregnant within 25 weeks of taking TEGSEDI). The purpose of this study is to learn more about the health of pregnant women who are taking or have taken TEGSEDI and the health of their babies.

Pregnant women with the polyneuropathy caused by hereditary transthyretin-mediated amyloidosis (hATTR-PN), who have not been exposed to TEGSEDI, are also eligible for this observational pregnancy study.

Your participation in this study will help Akcea Therapeutics Inc. to gather more information that could help women in the future and their doctors make more informed decisions.

Find Out More and Enroll

You are eligible to participate in either of the two scenarios outlined below:

You have taken at least 1 dose of TEGSEDI during your pregnancy or within 25 weeks of becoming pregnant;

OR

You have the polyneuropathy of hereditary transthyretin amyloidosis (hATTR-PN) and you are pregnant.

Within US:

1-877-465-7510

Hours of Operation:

Monday - Friday

8:00 a.m. to 5:00 p.m. Eastern Time

Email: TegsediPregnancy@UBC.com

Report a Pregnancy

Live Outside the US?

Email us at: TegsediPregnancy@UBC.com

to find out if you are eligible for this study.

Note: By providing your personal information via this website, you consent to a member of our Pregnancy Coordinating Center contacting you directly as follow-up to your report. Your personal information will not be used or shared for any other purpose.